or Try an Advanced Search...

    Gilead Sciences Stocks List

    Symbol Grade Name % Change
    GILD C Gilead Sciences, Inc. 1.27
    NRIX C Nurix Therapeutics, Inc. -1.19
    HEPA C Hepion Pharmaceuticals, Inc. -0.62
    HOOK F HOOKIPA Pharma Inc. -15.44
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Biopharmaceutical Biotechnology Cancer Hepatitis B Hepatotoxins Immunodeficiency Life Sciences Liver Disease Medicine Tenofovir Disoproxil Angina Antibiotics Bruton's Tyrosine Kinase Cardiovascular Disease Chronic Liver Disease Chronic Liver Diseases Coronavirus Cyclophilin Cystic Fibrosis Cytomegalovirus Retinitis

    Related ETFs - A few ETFs which own one or more of the above listed Gilead Sciences stocks.

    Symbol Grade Name Weight
    BBH D Market Vectors Biotech ETF 10.89
    IBBQ D Invesco Nasdaq Biotechnology ETF 10.11
    IBB D iShares Nasdaq Biotechnology Index Fund 9.94
    BIB F ProShares Ultra Nasdaq Biotechnology 7.63
    IDNA D iShares Genomics Immunology and Healthcare ETF 7.42
    View all Gilead Sciences ETFs...
    Compare ETFs
    Compare BBH to BIB Compare IBBQ to IBB Compare IBBQ to IDNA

        Gilead Sciences Stocks Recent News

        Date Stock Title
        Nov 20 NRIX Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
        Nov 20 GILD Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)
        Nov 18 GILD Gilead’s Livdelzi shows promise in PBC clinical trial
        Nov 17 NRIX Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
        Nov 17 HOOK Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky
        Nov 17 HOOK HOOKIPA Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
        Nov 15 GILD Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
        Nov 15 GILD Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
        Nov 15 HOOK HOOKIPA Pharma GAAP EPS of -$1.10, revenue of $4.7M
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Biopharmaceutical Biotechnology Cancer Hepatitis B Hepatotoxins Immunodeficiency Life Sciences Liver Disease Medicine Tenofovir Disoproxil Angina Antibiotics Bruton's Tyrosine Kinase Cardiovascular Disease Chronic Liver Disease Chronic Liver Diseases Coronavirus Cyclophilin Cystic Fibrosis Cytomegalovirus Retinitis
        Gilead Sciences

        Gilead Sciences, Inc. , is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
        Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

        More about Gilead Sciences
        Browse All Tags